CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists. Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“Moreover, HIF-1 -induced CXCL12 expression results in increased adhesion, migration and homing of CXCR4-positive progenitor cells to ischemic tissue [57].”
BackgroundThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×
“Thus, the angiogenic response induced by CXCL12 may at least in part be mediated by IL-8 [50].”
BackgroundA highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1101 · Cited by 1,482
Immune cell migration in inflammation: present and future therapeutic targets
Luster, A. D., Alon, R., & von Andrian, U. H. (2005) · Nature Immunology · doi:10.1038/ni1275 · Cited by 1,313
Crump, M. P., Gong, J., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana‐Seisdedos, F., Virelizier, J., Baggiolini, M., Sykes, B. D., & Clark‐Lewis, I. (1997) · The EMBO Journal · doi:10.1093/emboj/16.23.6996 · Cited by 731 · cited 2×
“The N-terminal end of CXCL12 is known to form an important CXCR4 receptor binding site [212].”
Background
Cited by
Cui Zhou, D., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 284
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
Targeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
“The importance of CXCR4 in tissue-specific metastasis has resulted in the development of several inhibitors of the CXCR4/SDF-1a axis [37,38].”
Bone Marrow Stem Cell Chemotactic Activity Is Induced by Elevated CXCl12 in Endometriosis
Moridi, I., Mamillapalli, R., Cosar, E., Ersoy, G. S., & Taylor, H. S. (2017) · Reproductive Sciences · doi:10.1177/1933719116672587 · Cited by 59
“The interaction between CXCR4 and CXCL12 allows the CXCR4– CXCL12 signaling axis to be involved in angiogenesis, tissue repair, migration, and invasion.(50) Bone marrow–derived stem cells that express the CXCR4 receptor migrate toward hESCs that express and secrete the CXCL12 ligand; this migration was further increas…”
Background
Metadata
- Authors
- Liekens, S., Schols, D., & Hatse, S.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-12-01
- Volume
- 16
- Issue
- 35
- Pages
- 3903-3920
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2118826168
- Cited by
- 213
- References
- 8
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. https://app.cochat.ai/papers/10.2174/138161210794455003
- The paper
- Liekens, S., Schols, D., & Hatse, S. (2010). CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. Current Pharmaceutical Design. https://doi.org/10.2174/138161210794455003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.